Pediatric adverse event reporting improvements
Executive Summary
FDA's Pediatric Advisory Committee will discuss ways to improve pediatric adverse event reporting during a half-day meeting on Feb. 14. The committee will also hear pediatric adverse event reports for Glucovance (glyburide/metformin), Xenical (orlistat), Viracept (nelfinavir), Lotensin (benazepril), Brevibloc (esmolol) and Malarone (atovaquone/proguanil). [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com]...